1. Home
  2. FNGR vs ACET Comparison

FNGR vs ACET Comparison

Compare FNGR & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FingerMotion Inc.

FNGR

FingerMotion Inc.

HOLD

Current Price

$1.02

Market Cap

65.0M

Sector

Technology

ML Signal

HOLD

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$8.62

Market Cap

77.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FNGR
ACET
Founded
2016
1947
Country
Singapore
United States
Employees
65
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
65.0M
77.3M
IPO Year
2014
2017

Fundamental Metrics

Financial Performance
Metric
FNGR
ACET
Price
$1.02
$8.62
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$48.33
AVG Volume (30 Days)
204.1K
143.0K
Earning Date
05-28-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$35,607,614.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.81
$0.46
52 Week High
$5.20
$9.05

Technical Indicators

Market Signals
Indicator
FNGR
ACET
Relative Strength Index (RSI) 50.03 68.64
Support Level $0.81 $6.28
Resistance Level $1.55 $9.03
Average True Range (ATR) 0.09 0.47
MACD 0.02 0.22
Stochastic Oscillator 72.46 93.43

Price Performance

Historical Comparison
FNGR
ACET

About FNGR FingerMotion Inc.

FingerMotion Inc is engaged in the provision of mobile payment and recharge services in the Chinese market. The company's business line includes Telecommunications Products and Services, Value Added Products and Services, Short Message Services (SMS) and Multimedia Messaging Services (MMS); a Rich Communication Services (RCS) platform; Data Insights; and a Video Games Division (inactive). It principally earns revenue by providing mobile payment and recharge services to customers of telecommunications companies in China.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).

Share on Social Networks: